Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer
Background Programmed death 1 (PD-1) inhibitor demonstrated durable antitumor activity in advanced esophageal squamous cell carcinoma (ESCC), but the clinical benefit of perioperative immunotherapy in ESCC remains unclear. This study evaluated the efficacy and safety of neoadjuvant chemoradiotherapy...
Saved in:
| Main Authors: | Qiang Liu, Qing Ye, Xin Xu, Lei Shen, Yao Zhang, Bin Hu, Haiyan Chen, Xiaojing Zhao, Zhiyong Sun, Haiping Lin, Ling Rong, Xiaohang Wang, Yong-Rui Bai, Xiumei Ma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/3/e008631.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma
by: Jun-Peng Lin, et al.
Published: (2025-08-01) -
Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
by: Canjun Li, et al.
Published: (2025-04-01) -
Neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma: does everyone need it?
by: D. A. Chichevatov, et al.
Published: (2024-05-01) -
Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy
by: Kunhan Ni, et al.
Published: (2025-06-01) -
Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma
by: Likun Liu, et al.
Published: (2025-08-01)